These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26732970)

  • 21. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
    Sivolella S; De Biagi M; Brunello G; Berengo M; Pengo V
    Odontology; 2015 Sep; 103(3):258-63. PubMed ID: 25656043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
    Enríquez A; Baranchuk A; Corbalán R
    Rev Med Chil; 2019; 147(1):73-82. PubMed ID: 30848768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
    Shaw J; de Wit C; Le Gal G; Carrier M
    J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Novel Oral Antithrombotics With the Risk of Intraocular Bleeding.
    Uyhazi KE; Miano T; Pan W; VanderBeek BL
    JAMA Ophthalmol; 2018 Feb; 136(2):122-130. PubMed ID: 29242919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
    Elewa H; El-Makaty H; Ali Z
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
    JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.
    Adachi T; Hoshino H; Takagi M; Fujioka S;
    Cerebrovasc Dis Extra; 2017; 7(1):62-71. PubMed ID: 28376486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio.
    Bernier M; Lancrerot SL; Parassol N; Lavrut T; Viotti J; Rocher F; Drici MD
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):472-477. PubMed ID: 33030858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R; Smith RE; Henry BL
    J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
    Chang TW; Arpey CJ; Baum CL; Brewer JD; Hochwalt PC; Hocker TL; Roenigk RK; Otley CC
    Dermatol Surg; 2015 Jul; 41(7):784-93. PubMed ID: 26057410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.